Abstract: Disclosed are agents and methods for treating unwanted or deleterious immune responses. More particularly, the present invention discloses neuritin agents for use in inhibiting plasma cell (PC) differentiation, reducing the number of autoreactive B cells, treating, or inhibiting the development or progression of, autoreactive B cell disorders including B cell-mediated autoimmune diseases and IgE-mediated disorders and of monoclonal gammopathies and PC dyscrasias.

Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.

Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.

Abstract: An agent for inhibiting binding of transferrin receptor to SARS-CoV-2 spike protein or an anti-SARS-CoV-2 medicament is provided, where active pharmaceutical ingredients of the agent or the medicament include interference peptides, and the interference peptides include: SL8, FG8, DL12, RK4, SD6, HF7, and/or QK8.

Abstract: Provided is a teverelix-TFA composition having a molar ratio of teverelix to trifluoroacetate composition of at least 1:2.2. Such a molar ratio will prevent undesirable gel-formation and provide a homogenous suspension, whereby a unique bioavailablity of teverelix is obtained.

Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.

Abstract: In the invention, a pharmaceutical composition is provided, comprising a first and a second peptide. The first peptide is a peptide of the bacteriocin PLNC8 ??, wherein the peptide of the bacteriocin PLNC8 ?? is a peptide A having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) with SEQ ID NO 1, or a peptide B having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) with SEQ ID NO 2. When the first peptide is peptide A, the second peptide B? having 14 to 34 amino acids and comprising a peptide having at least 90%>, 95%>, 96%>, 97%>, 98%> or 99% sequence identity (% SI) with SEQ ID NO 3. When the first peptide is peptide B, the second peptide A? having 15 to 29 amino acids and comprising a peptide having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) with SEQ ID NO 4. The pharmaceutical composition further comprises at least one antibiotic. The pharmaceutical composition may be used in the treatment or prophylaxis of a bacterial infection.

Abstract: Compositions and methods are provided for use in binding opioids, such as 6-MAM, morphine, heroin, hydrocodone, oxycodone, meperidine, and fentanyl, while avoiding binding to OUD treatment agents, such as naloxone and naltrexone. Methods are also provided for use in a systematic structure-based virtual screening and design approach for identification of such antibodies. Methods are also provided for use in treating OUD. Methods are also provided for use in detecting an opioid in a sample.

Abstract: The present disclosure relates to a peptide consisting of an amino acid sequence of SEQ ID NO: 1, 2, 3, or 4, a pharmaceutical composition for preventing or treating skin disease including the peptide, a cosmetic composition for skin condition improvement including the peptide, a food composition for skin condition improvement including the peptide, a method of preventing or treating skin disease using the peptide, and a use of the peptide in preventing or treating skin disease or improving skin condition.

Abstract: COVID-19 results from the infection of the SARS-CoV-2 virus and has spread quickly to literally infected the world. Although coronavirus spike proteins can recognize a broad range of host cell-surface proteins, inhibiting spike protein binding to a survival factor called GRP78 results in a significant reduction in SARS-CoV-2 attachment, entry and replication in lung and kidney cells. This inhibition is accomplished with a novel type of inhibitor that potently blocks the binding of SARS-CoV-2 spike protein and whole virus to surface-bound GRP78. These novel GRP78 inhibitors also down regulate cytokines (IL10, IL6), immune co-inhibitory checkpoint proteins (PD-L1, B7H3, B7H4), and up regulate immune co-stimulatory proteins (MHC-II, CD-86) resulting in the reduction of the immune suppressive nature of infected lung alveolar epithelial cells in vitro and in vivo. Finally, these novel GRP78 inhibitors inhibit the hyperfibrinolysis of infected lung cells by reducing the activation of plasmin on cell surfaces.

Abstract: Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols.

Abstract: Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

Abstract: The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.

Abstract: A cell hydrolysate composition is described, wherein the composition comprises substantially all protein polypeptides and/or polypeptide fragments derived substantially from all the proteins in a cell from an in vitro cell culture.

Abstract: Disclosed are a novel protein variant for controlling fibrosis of amyloid beta and a composition for treating neurodegenerative diseases using the same.

Abstract: A multivalent polymer includes a multimerization peptide domain and a target protein fused directly or indirectly with the multimerization peptide domain. The multivalent polymer exhibits a probe effect by establishing a nano-size by self-assembly, and, accordingly, the multivalent polymer can be advantageously used in the development of a highly sensitive protein nano chip and the development of a diagnostic kit.

Abstract: The present invention relates to peptides and pharmaceutical compositions thereof for treating eye diseases. Administering peptides of the present invention to the eye can increase the amount of tear secretion and repair corneal damage. Thus, these peptides and compositions can be advantageously used as therapeutic agents for treating eye diseases.

Abstract: Described herein is a composition for delivery of an active agent. The composition includes a peptide coacervate, wherein the peptide coacervate includes one or more peptides derived from histidine-rich proteins, and an active agent encapsulated in the peptide coacervate. Further provided are a method for encapsulation of an active agent in a peptide coacervate, a method for delivery of an active agent, and a method for treating or diagnosing a condition or disease in a subject in need thereof.

Abstract: The present invention provides pharmaceutical compositions of teixobactin that are capable of preventing gelation of teixobactin. The pharmaceutical compositions comprise teixobactin and a pegylated phospholipid. The present invention also provides methods of preparing the pharmaceutical compositions of teixobactin and methods of treating a subject using the pharmaceutical compositions of teixobactin.

Abstract: Cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds are provided that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. Also provided are improved methods for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.